Letter  to the editor

A Amirkhosravi; JL Francis

doi:10.4414/smw.2011.13278

Technical comment

Vol. 141 No. 4142 (2011)

Letter to the editor

A Amirkhosravi
JL Francis

DOI: https://doi.org/10.4414/smw.2011.13278
Cite this as:: Swiss Med Wkly. 2011;141:w13278
Published: 10.10.2011

References

Fehr M, Catschegn S, Reinhart WH, Madon J, Asmis L, Cathomas R, von Moos R. The influence of bevacizumab on platelet function. Swiss Med Wkly. 2011;141:w13243.
Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171–81.
Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure. 1998;6(5):637–48.
See http://datasheets.scbt.com/sc-4570.pdf, accessed 15-August-2011. SCBT technical support also provided the amino acid sequence of VEGF (hBA-165) [sc-4570], confirming the absence of the heparin-binding domain.
Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost.2008;34(8):709–33.
Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg. 2006;63(5):334–7.
Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A. 2007;104(9):3478–83.
Caine GJ, Blann AD. Soluble p-selectin should be measured in citrated plasma, not in serum. Br J Haematol. 2003;121(3):530–2.

How to Cite

1.

Amirkhosravi A, Francis J. Letter to the editor. Swiss Med Wkly [Internet]. 2011 Oct. 10 [cited 2024 Nov. 23];141(4142):w13278. Available from: https://smw.ch/index.php/smw/article/view/1355

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

[1] Fehr M, Catschegn S, Reinhart WH, Madon J, Asmis L, Cathomas R, von Moos R. The influence of bevacizumab on platelet function. Swiss Med Wkly. 2011;141:w13243.

[2] Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost. 2009;7(1):171–81.

[3] Fairbrother WJ, Champe MA, Christinger HW, Keyt BA, Starovasnik MA. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure. 1998;6(5):637–48.

[4] See http://datasheets.scbt.com/sc-4570.pdf, accessed 15-August-2011. SCBT technical support also provided the amino acid sequence of VEGF (hBA-165) [sc-4570], confirming the absence of the heparin-binding domain.

[5] Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost.2008;34(8):709–33.

[6] Heinzerling JH, Huerta S. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg. 2006;63(5):334–7.

[7] Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A. 2007;104(9):3478–83.

[8] Caine GJ, Blann AD. Soluble p-selectin should be measured in citrated plasma, not in serum. Br J Haematol. 2003;121(3):530–2.